Tradestie Institutional Equity Comparison Engine
STLN vs XLO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
XLO Overall Edge
XLO Captures Institutional Edge (3โ0 Pillars ยท 8โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Xilio Therapeutics, Inc. Common Stock (XLO) driven by superior Valuation, Growth & Margin, Momentum & Technical. Fundamentally, STLN trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus XLO at N/M Forward P/E and -74.9% operating margin (-47.6% YoY). In options structure, STLN sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against XLO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
XLO
STLN N/M vs XLO N/M Fwd P/E
Growth & Margin Winner
XLO
Op Margin N/A vs -74.9% ยท YoY N/A vs -47.6%
Momentum & Technical Winner
XLO
1Y -42.0% vs +836.8% ยท 52W Pos 1% vs 75%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
STLN
US Equity
STLN
Institutional Equity
$3.00
-5.66% 1D
Market Cap
N/A
1M Return
-56.58%
1Y Return
-41.97%
Forward P/E
N/M
Unified AI Score
46.6 / 100
HOLD
Tech 45.0
Fund 46.0
Flow 50.0
Mom 55.0
XLO
NASDAQ
Xilio Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$7.56
+0.67% 1D
Market Cap
$53.1M
1M Return
-5.85%
1Y Return
+836.8%
Forward P/E
N/M
Unified AI Score
45.8 / 100
HOLD
Tech 40.0
Fund 50.0
Flow 50.0
Mom 74.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
STLN -41.97%
XLO +836.8%
Spread: +25.14 pp (XLO Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
STLN TTM Op. Margin: N/A
XLO TTM Op. Margin: -74.9%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on STLN vs XLO. Trailing 12-month operating profitability (STLN N/A vs XLO -74.9%) and valuation multiples (STLN N/M vs XLO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | STLN | XLO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | N/A | $53.1M | Larger Scale | XLO |
| Trailing P/E Ratio Valuation | N/M | 11.6x | Lower Multiple | XLO |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | N/A | -47.6% | Higher Growth | XLO |
| Operating Margin (TTM) Profitability | N/A | -74.9% | Higher Margin | XLO |
| Net Profit Margin Profitability | N/A | -20.9% | Higher Margin | XLO |
| Return on Equity (ROE) Capital Efficiency | N/A | -38.2% | Higher ROE | XLO |
| 52-Week Range Position Momentum | 1% ($3โ$7) | 75% ($0โ$10) | Stronger Trend | XLO |
| Beta / 30D Volatility Risk Regime | 1.42ฮฒ ยท 175% Vol | 0.74ฮฒ ยท 63% Vol | Lower Realized Risk | XLO |
| Unified Institutional Score Composite Signal | 46.6 / 100 (HOLD) | 45.8 / 100 (HOLD) | Higher Composite | STLN |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full STLN vs XLO Buy Guide
STLN
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
XLO
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither STLN nor XLO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.